Novo Nordisk is experiencing sustained margin compression due to increasing price competition in the GLP-1 weight loss drug market. Its gross profit margin has dropped from over 84% to 80%, and profit margin from over 36% to 33%, with further declines expected. Direct-to-consumer programs and competition have eroded self-pay margins for its drug Wegovy, while upcoming patent expirations and oral drug formulations threaten future profitability and pricing power. These challenges highlight risks to Novo Nordisk's earnings and long-term growth prospects.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
